Sarpogrelate
Sarpogrelate is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C, and 5-hydroxytryptamine receptor 2A.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | 1 | — | — | 2 | — | 3 | |
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | 2 | — | 3 | |
| Chronic renal insufficiency | D051436 | N18 | — | — | 1 | 1 | — | 2 | |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | 1 | |
| Blood viscosity | D001809 | EFO_0004301 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral infarction | D002544 | I63 | — | — | 2 | — | — | 2 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 1 | 1 |
| Arteriosclerosis obliterans | D001162 | EFO_1000820 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SARPOGRELATE |
| INN | sarpogrelate |
| Description | Sarpogrelate is a stilbenoid and a hemisuccinate. |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 125926-17-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL52939 |
| ChEBI ID | — |
| PubChem CID | 5160 |
| DrugBank | DB12163 |
| UNII ID | 19P708E787 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR2B
HTR2B
HTR2C
HTR2C
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 527 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
77 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more